Sold as Phosphotope, Sodium Phosphate P 32. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 2 applications for Sodium Phosphate P-32 (sold as Phosphotope, Sodium Phosphate P 32), first approved May 2, 1957, with 0 new uses approved and 0 published complete response letters.
| May 2, 1957 | PhosphotopeNDA 10927 · New formulation or manufacturer | Bracco | 7 | Discontinued |
| Mar 4, 1959 | Sodium Phosphate P 32NDA 11777 · New formulation or manufacturer | Mallinckrodt | 11 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Mallinckrodt